A novel aminosteroid is active for proliferation inhibition and differentiation induction of human acute myeloid leukemia HL-60 cells.
A novel aminosteroid, 2beta-(4'-methyl-1'piperazinyl)-3alpha,17beta-dihydroxyl+ ++-5alpha-androstane (HY), was found to inhibit proliferation of HL-60 leukemia cells and induce these cells to differentiate toward macrophage-like cells from the following evidence. (1) It inhibited HL-60 cell proliferation by cell counts, colony counts and MTT assay; (2) It caused morphological changes toward macrophage-like cells after culture for 6 days; (3) It induced NBT reduction activity; (4) It induced alpha-naphthyl acetate esterase activity and (5) it induced CD11b and CD14 expression indicated by flow cytometry analysis. There is potential for this novel aminosteroid in the treatment of myeloid leukemia.
He
Q
Q
Research Laboratory of Blood Physiology, Hunan Medical University, Changsha, PR China.
Jiang
D
D
D015113:Androstane-3,17-diol / Q000031:analogs & derivatives* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D006131:Growth Inhibitors / Q000494:pharmacology*; D018922:HL-60 Cells; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000473:pathology*
C078540:3,17-dihydroxy-17-methylandrostane-2-carboxylic acid; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D015113:Androstane-3,17-diol